Our mission is to research, develop, and deliver innovative medicines to improve and extend people’s lives with cancer.
MAIA Biotechnology, Inc. is a targeted therapy, immuno-oncology company, focused on development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer.
Investigational drug candidates and research:
Ateganosine (THIO), our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Read more about ateganosine (THIO).
Our ateganosine (THIO) program drives our development pipeline of second-generation telomere targeting agents.
